antipsychotic

Alexza Pharmaceuticals shares are tanking in early trading after the company announced today that the U.S. Food and Drug Administration has not approved its AZ-004, an antipsychotic inhaled drug for treating agitation in schizophrenia or bipolar-disorder patients.

It was just at the end of October that the Journal of the American Medical Association published a study which found that children taking the latest generation of antipsychotic drugs gain significant amounts of weight -- as much as 18.7 pounds on average in just 11 weeks. Young people taking Eli...